Effects of thalidomide on the development of bone damage caused by prednisolone in rats

Pharmacological Reports

Volumn 64, Issue 2, 2012, Pages 386-395

  Kaczmarczyk Sedlak, Ilona ^a   Zych, Maria ^a   Rotko, Katarzyna ^a   Sedlak, Lech ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bone; Glucocorticosteroids; Osteoporosis; Prednisolone; Rat; Thalidomide

Indexed keywords

THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BONE MASS; BONE STRUCTURE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG MECHANISM; MALE; MORPHOMETRICS; NONHUMAN; RAT; WISTAR RAT;

EID: 84862170984     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(12)70779-x     Document Type: Article

References (46)

1. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A et al.: Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 2006, 107, 3098-3105.
2. Angeli A, Osella G, Reimondo G, Terzolo M: Glucocorticoid- induced osteoporosis: recent findings: Ann Ital Med Int, 2000, 15, 47-55.
3. Benvenuti S, Brandi ML: Corticosteroid-induced osteoporosis: Pathogenesis and prevention. Clin Exp Rheumatol, 2000,18, 64-66.
4. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D et al.: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia, 2008, 22, 1925-1932.
5. Canalis E, Delany AM: Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci, 2002, 966, 73-81. (Pubitemid 34729163)
6. Ching DW, McClintock A, Beswick F: Successful treatment with low-dose thalidomide in a patient with both Behcet's Disease and Complex Regional Pain Syndrome Type I: Case Report. J Clin Rheumatol, 2003, 9, 96-98. (Pubitemid 36531881)
7. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ: Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid- induced and postmenopausal osteoporosis. J Bone Miner Res, 2001, 16, 97-103. (Pubitemid 32046193)
8. Delany AM, Durant D, Canalis E: Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol, 2001, 15, 1781-1789. (Pubitemid 32939308)
9. de Matteo M, Brunetti AE, Maiorano E, Cafforio P, Dammacco F, Silvestris F: Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effects of bortezomib and lenalidomide. Leuk Res, 2010, 34, 243-249.
10. Folwarczna J, Śliwiński L, Cegieła U, Pytlik M, Kaczmarczyk-Sedlak I, Nowińska B, Janiec W, Trzeciak HI: Raloxifene similarly affects the skeletal system of male and ovariectomized female rats. Pharmacol Rep, 2007, 59, 349-358. (Pubitemid 47299736)
11. Frost HM: Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res, 1969, 3, 211-237.
12. Haslett PA: Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol, 1998, 25, 53-57.
13. Kaczmarczyk-Sedlak I: Modification of bone remodeling by thalidomide in rats (Polish). Habilitation Thesis, Medical University of Silesia, 2008.
14. Kaczmarczyk-Sedlak I, Cegieła U, Nowińska B, Folwarczna J: Effects of catecholamines on the intramedullary pressure in the femur in rats with prednisoloneinduced osteoporosis. Pharmacol Rep, 2006, 58, 540-550. (Pubitemid 44383280)
15. Kaczmarczyk-Sedlak I, Folwarczna J, Trzeciak HI: Thalidomide affects the skeletal system of ovariectomized rats. Pharmacol Rep, 2009, 61, 529-538.
16. Kaplan G, Thomas S, Fierer DS, Mulligan K, Haslett PA, Fessel WJ, Smith LG et al.: Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses, 2000, 16, 1345-1355.
17. Lan CC, Lin CL, Wu CS, Chai CY, Chen WT, Chen GS: Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. J Dermatol, 2007, 34, 237-242.
18. Lane NE, Lukert B: The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am, 1998, 27, 465-483. (Pubitemid 28285876)
19. Lindgren JU, DeLuca HF, Mazess RB: Effects of 1,25(OH)2D3 on bone tissue in the rabbit: studies on fracture healing, disuse, osteoporosis, and prednisone osteoporosis. Calcif Tissue Int, 1984, 36, 591-595. (Pubitemid 15157116)
20. Locker D, Superstine E, Sulman FG: The mechanism of the push and pull principle. 8. Endocrine effects of thalidomide and its analogues. Arch Int Pharmacodyn, 1971, 194, 39-55.
21. Manolagas SC, Weinstein RS: New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res, 1999, 14, 1061-1066. (Pubitemid 29314048)
22. Melchert M, List A: The thalidomide saga. Int J Biochem Cell Biol, 2007, 39, 1489-1499. (Pubitemid 47031027)
23. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Minshi NC et al.: Apoptotic signaling induced by immunomadulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 2002, 99, 4525-4530. (Pubitemid 34627223)
24. Moghadam-Kia S, Werth VP: Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol, 2010, 49, 239-248.
25. Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, Kubo T et al.: Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol, 2008, 33, 129-136.
26. Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A, Ozaki S, Nakao K: High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int, 2006, 17, 105-108. (Pubitemid 41798034)
27. Noa M, Mendoza S, Más R, Mendoza N, León F: Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague Dawley rats. Drugs R D, 2004, 5, 281-290. (Pubitemid 39429516)
28. Ohlson C, Bengtsson B, Isaksson OGP, Andreassen TT, Slootweg MC: Growth hormone and bone. Endocr Rev, 1998, 19, 55-79. (Pubitemid 29122074)
29. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R: Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun, 2004, 318, 259-264. (Pubitemid 38526274)
30. Okafor MC: Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy, 2003, 23, 481-493.
31. Ortoft G, Brüel A, Andreassen TT, Oxlund H: Growth hormone is not able to counteract osteopenia of rat cortical bone induced by glucocorticoid with protracted effect. Bone, 1995, 17, 543-548. (Pubitemid 26017575)
32. Ortoft G, Oxlund H: Qualitative alterations of cortical bone in female rats after long-term administration of growth hormone and glucocorticoid. Bone, 1996, 18, 581-590. (Pubitemid 26257880)
33. Ortoft G, Oxlund H, Andreassen TT: Administration of a glucocorticoid with depot effect counteracts the stimulating effect of growth hormone on cancellous and cortical bone of the vertebral body in rats. Calcif Tissue Int, 1998, 63, 14-21. (Pubitemid 28289929)
34. Patschan D, Loddenkemper K, Buttgereit F: Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone, 2001, 29, 498-505. (Pubitemid 33124290)
35. Pennisi P, D'Alcamo MA, Leonetti C, Clementi A, Cutuli VM, Riccobene S, Parisi N, Fiore CE: Supplementation of L-arginine prevents glucocorticoid- induced reduction of bone growth and bone turnover abnormalities in a growing rat model. J Bone Miner Metab, 2005, 23, 134-139. (Pubitemid 40591036)
36. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM: Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 2010, 24, 22-32.
37. Reid IR: Glucocorticoid effects on bone. J Clin Endocrinol Metab, 1998, 83, 1860-1862.
38. Reid IR, Heap SW: Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med, 1990, 150, 2545-2548.
39. Rieman DJ, McClung HA, Dodds RA, Hwang SM, Holmes MW, James IE Drake FH, Gowen M: Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone, 2001, 28, 282-289. (Pubitemid 32192952)
40. Shah SK, Gecys GT: Prednisone-induced osteoporosis: an overlooked and undertreated adverse effect. JAOA, 2006, 106, 653-657. (Pubitemid 46045149)
41. Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS: Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res, 2005, 20, 390-399.
42. Steinbuch M, Youket TE, Cohen S: Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int, 2004, 15, 323-328. (Pubitemid 38543952)
43. Terpos E, Dimopoulos MA, Sezer O: The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myleoma. Leukemia, 2007, 21, 1875-1884. (Pubitemid 47299959)
44. Tkocz-Kwiatkowska J, Karczmarczyk-Sedlak I, Folwarczna J: Effect of pamidronate on the development of changes in bone mechanical properties and bone structure caused by the administration of prednisolone in rats. Pol J Pharmacol, 1998, 50, 253-258. (Pubitemid 28374778)
45. Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G et al.: First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Hematol, 2006, 76, 399-404.
46. United States Pharmacopeia Dispensing Information. Volume I. Drug information for the health care professional. Houghton Mifflin Company, Rockville, 2004, 2648-2653.